BioMarin Pharmaceutical Inc. (BMRN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,860 | 1,846 | 2,096 | 2,419 | 2,854 | 0 | 3,407 | 3,907 |
| Operating profit | $m | 533 | 273 | ||||||
| Net profit | $m | 854 | -64 | 142 | 168 | 427 | 27 | 73 | 994 |
| EPS reported | $ | 1.80 | 0.39 | ||||||
| Operating cashflow per share | $ | 4.32 | 4.44 | ||||||
| Capex per share | $ | 0.54 | 0.64 | ||||||
| FCF per share | $ | 3.78 | 3.80 | ||||||
| Free cash flow | $m | 725 | 733 | ||||||
| Net debt | $m | -955 | 3,312 | ||||||
| Book value equity | $m | 6,087 | 6,322 | ||||||
| Book value per share | $ | 30.84 | 32.56 | ||||||
| Number of shares | m | 197.39 | 194.15 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 33.02 | 154.51 | ||||||
| P/B LTM | x | 1.87 | 1.80 | ||||||
| P/S LTM | x | 3.54 | 3.35 | ||||||
| P/FCF LTM | x | 15.72 | 15.55 | ||||||
| EV/EBITDA LTM | x | 18.73 | 27.82 | ||||||
| EV/Sales LTM | x | 3.33 | 4.75 | ||||||
| Earnings Yield LTM | % | +3.03% | +0.65% | ||||||
| FCF Yield | % | +6.36% | +6.43% | ||||||
| Quality | |||||||||
| ROE | % | +5.73% | +1.18% | ||||||
| ROIC | % | +5.64% | +1.25% | ||||||
| Operating margin | % | +16.56% | +8.02% | ||||||
| Gross margin | % | +77.13% | +75.55% | ||||||
| FCF/Sales | % | +22.51% | +21.51% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -18.55% | -82.35% | ||||||
| Sales Growth YoY | % | +12.87% | +19.37% | ||||||
| Net Income Growth YoY | % | -18.26% | -82.90% | ||||||
| FCF Growth | % | +52.49% | +54.15% | ||||||
| Operating Profit Growth | % | +10.17% | -43.57% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 1.13 | 0.17 | ||||||
| Net Debt/EBITDA | x | -1.17 | 8.63 | ||||||
| EBIT/Net interest | x | 48.95 | 3.27 | ||||||
| Net debt/market cap | % | +5.32% | +32.55% | ||||||
| Net debt/Equity | x | -0.16 | 0.52 | ||||||
| Gross debt/equity | x | 0.11 | 0.66 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
BioMarin Pharmaceutical Inc. (BMRN)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free